Ascendis Pharma A/S (ASND)

NASDAQ: ASND · IEX Real-Time Price · USD
122.96
3.91 (3.28%)
At close: Jan 14, 2022 4:00 PM
130.00
7.04 (5.73%)
After-hours:Jan 14, 2022 7:30 PM EST
Market Cap7.00B
Revenue (ttm)4.02M
Net Income (ttm)-489.98M
Shares Out56.94M
EPS (ttm)-8.75
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume246,404
Open119.05
Previous Close119.05
Day's Range116.79 - 128.49
52-Week Range109.36 - 178.71
Beta0.72
AnalystsBuy
Price Target193.52 (+57.4%)
Earnings DateNov 10, 2021

About ASND

Ascendis Pharma A/S, a biopharmaceutical company, develops therapeutics for unmet medical needs. The company develops TransCon growth hormone, which completed Phase III clinical trials for growth hormone deficiency. It also develops TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for achondroplasia. In addition, the company develops preclinical studies in the field of oncology for potential product candidates and evaluate systemic and localized delivery systems using its TransCon technologies. The company was incorpo...

IndustryBiotechnology
IPO DateJan 28, 2015
CEOJan Moeller Mikkelsen
Employees482
Stock ExchangeNASDAQ
Ticker SymbolASND
Full Company Profile

Financial Performance

Financial numbers in millions EURFinancial Statements

Analyst Forecast

According to 12 analysts, the average rating for ASND stock is "Buy." The 12-month stock price forecast is 193.52, which is an increase of 57.39% from the latest price.

Price Target
$193.52
(57.39% upside)
Analyst Consensus: Buy

News

Ascendis' (ASND) TransCon hGH Gets EU Nod for Pediatric GHD

Ascendis Pharma (ASND) gets nod in Europe for TransCon hGH for the treatment of pediatric growth hormone deficiency.

2 days ago - Zacks Investment Research

Ascendis Pharma's Growth Hormone Deficiency Med Scores European Approval

The European Commission (EC) has granted marketing authorization to Ascendis Pharma A/S's (NASDAQ: ASND) Lonapegsomatropin (developed under the name TransCon hGH). The approval for TransCon covers a onc...

3 days ago - Benzinga

Ascendis Pharma A/S Receives European Approval for TransCon™ hGH for Pediatric Growth Hormone Deficiency

TransCon hGH (approved by the European Commission as Lonapegsomatropin Ascendis Pharma) is a once-weekly prodrug of somatropin for pediatric patients diagnosed with growth hormone deficiency TransCon hG...

3 days ago - GlobeNewsWire

Ascendis Pharma A/S to Host Virtual R&D Program Update on December 14

COPENHAGEN, Denmark, Dec. 07, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the Company will host a virtual R&D Program Update for the investment community on Tuesday,...

1 month ago - GlobeNewsWire

Ascendis' Hypoparathyroidism Candidate Shows Durable Benefit At 84 Weeks

Ascendis Pharma A/S (NASDAQ: ASND) announced topline results from Week 84 of its Phase 2 PaTH Forward Trial of its TransCon PTH candidate hypoparathyroidism (HP).  Hypoparathyroidism is a condition in w...

1 month ago - Benzinga

Ascendis Pharma A/S Announces Top-Line Results from Week 84 of Its Phase 2 PaTH Forward Trial Demonstrating that Tran...

–– 58 of the original 59 subjects continue in the open-label extension portion of the Phase 2 trial.

1 month ago - GlobeNewsWire

Ascendis Pharma A/S to Participate in the Evercore ISI 4th Annual HealthCONx Conference

COPENHAGEN, Denmark, Nov. 17, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the Company is scheduled to participate in the Evercore ISI 4th Annual HealthCONx Conferenc...

1 month ago - GlobeNewsWire

Ascendis (ASND) Gets Positive CHMP Opinion for GHD Drug Filing

Ascendis Pharma (ASND) is seeking approval for TransCon hGH for the treatment of pediatric growth hormone deficiency in Europe.

2 months ago - Zacks Investment Research

Ascendis Pharma A/S Receives Positive CHMP Opinion for TransCon™ hGH for Patients with Pediatric Growth Hormone Defic...

– TransCon hGH is a once-weekly prodrug of somatropin designed to reduce the treatment burden for patients with growth hormone deficiency.

2 months ago - GlobeNewsWire

Ascendis Pharma A/S Reports Third Quarter 2021 Financial Results

– SKYTROFA ® (lonapegsomatropin-tcgd) approved by the FDA in the U.S. as a once-weekly treatment for pediatric growth hormone deficiency (GHD); commercially launched in October 2021.

2 months ago - GlobeNewsWire

Ascendis Pharma A/S Announces Third Quarter 2021 Financial Results and Business Update Conference Call on November 10

COPENHAGEN, Denmark, Nov. 03, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), today announced that the Company will hold a conference call and live webcast on Wednesday, November 10, 2021 a...

2 months ago - GlobeNewsWire

Ascendis Pharma A/S Announces U.S. Commercial Launch of SKYTROFA® (Lonapegsomatropin-tcgd), the First and Only FDA Ap...

COPENHAGEN, Denmark, Oct. 15, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), today announced the U.S. commercial launch of SKYTROFA (lonapegsomatropin-tcgd), its once-weekly treatment for ...

3 months ago - GlobeNewsWire

Ascendis Pharma A/S Announces Presentations for TransCon™ PTH and TransCon™ CNP at the American Society for Bone & Mi...

– Late-breaking oral presentation will feature a comprehensive review of 58-week results  from the company's Phase 2 PaTH Forward Trial –

3 months ago - GlobeNewsWire

Ascendis Pharma A/S Announces Share Repurchase Program

COPENHAGEN, Denmark, Sept. 29, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to potentially create new trea...

3 months ago - GlobeNewsWire

Ascendis Pharma A/S Announces Mean Bone Mineral Density (BMD) Data from Phase 2 PaTH Forward Trial Demonstrating Cont...

– Data from subjects with available dual energy x-ray absorptiometry (DXA) scans demonstrated stabilization of BMD, in alignment with observed bone turnover markers previously reported –

3 months ago - GlobeNewsWire

Ascendis (ASND) Seeks FDA Nod for New Immunotherapy Study

Ascendis (ASND) plans to develop a sustained-release immunotherapy to treat advanced cancer developed using its TransCon platform.

4 months ago - Zacks Investment Research

Ascendis Pharma A/S Announces Upcoming Investor Presentations

COPENHAGEN, Denmark, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to potentially create new trea...

4 months ago - GlobeNewsWire

Ascendis Pharma A/S Submits Investigational New Drug Application to Initiate TransCon™ IL-2 β/γ Clinical Program

– TransCon IL-2 β/γ  is an investigational long-acting prodrug designed to improve cancer immunotherapy through the sustained systemic release of an IL-2 variant with potential for prolonged activation ...

4 months ago - GlobeNewsWire

Ascendis Pharma A/S Announces Pricing of Public Offering of ADSs

COPENHAGEN, Denmark, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to potentially create new trea...

4 months ago - GlobeNewsWire

Ascendis Pharma A/S Announces Proposed Public Offering of ADSs

COPENHAGEN, Denmark, Aug. 31, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to potentially create new treat...

4 months ago - GlobeNewsWire

Attention Biotech Investors: Mark Your Calendar For September PDUFA Dates

August proved to be a mixed month for regulatory approvals, with the Food and Drug Administration approving a few, turning down a few others and delaying the remaining. New molecular entity approvals – ...

Other symbols:CARAJAZZSESNSNY
4 months ago - Benzinga

Ascendis (ASND) Rallies on First FDA-Approved Drug Skytrofa

Ascendis' (ASND) Skytrofa gets FDA approval for treating growth failure in pediatric patients. The drug is also the first FDA-approved product in the company's portfolio.

4 months ago - Zacks Investment Research

Why Shares of Ascendis Soared This Week

The pharmaceutical company saw its shares jump more than $26.

4 months ago - The Motley Fool

Here's Why Ascendis Pharma Shares Are Surging Higher Today

Approval of the company's weekly growth hormone is making investors smile today.

4 months ago - The Motley Fool

See Why Ascendis Pharma Stock Is Shining On Thursday

The FDA on Wednesday gave a thumbs-up to Ascendis Pharma A/S's (NASDAQ: ASND) long-acting growth hormone lonapegsomatropin-tcgd. Marketed as Skytrofa, the somatropin prodrug has been approved in kids ag...

4 months ago - Benzinga